Search
01/10/2021
Systematic literature review of burden of illness in chronic inflammatory demyelinating polyneuropathy (CIDP)
Querol, L, Crabtree, M, Herepath, M, Priedane, E, Viejo, IV, Agush, S, Sommerer, P. Systematic literature review of burden of illness in chronic inflammatory demyelinating polyneuropathy (CIDP). JOURNAL OF NEUROLOGY. 2021; 268(10)DOI:10.1007/s00415-020-09998-8. PMID:32583051. IF:6.682(Q1/2D).
01/10/2021
Autoimmune nodopathies: treatable neuropathies beyond traditional classifications comment
Querol, L. Autoimmune nodopathies: treatable neuropathies beyond traditional classifications comment. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY. 2021; 92(10)DOI:10.1136/jnnp-2021-326676. PMID:34400541. IF:13.654(Q1/1D).
01/10/2021
Novel Immunological and Therapeutic Insights in Guillain-Barre Syndrome and CIDP
Querol, L, Lleixa, C. Novel Immunological and Therapeutic Insights in Guillain-Barre Syndrome and CIDP. Neurotherapeutics. 2021; 18(4)DOI:10.1007/s13311-021-01117-3. PMID:34549385. IF:6.088(Q1/2D).
01/10/2021
Effects of a Green Oat Herb Extract on Cognitive Performance and Neurophysiological Activity: A Randomized Double-Blind Placebo-Controlled Study
Martinez-Horta, S, Ivanir, E, Perrinjaquet-Moccetti, T, Keuter, MH, Kulisevsky, J. Effects of a Green Oat Herb Extract on Cognitive Performance and Neurophysiological Activity: A Randomized Double-Blind Placebo-Controlled Study. Frontiers in Neuroscience. 2021; 15DOI:10.3389/fnins.2021.748188. PMID:34658781. IF:5.152(Q2/4D).
01/10/2021
A Phase II Study to Evaluate the Safety and Efficacy of Prasinezumab in Early Parkinson's Disease (PASADENA): Rationale, Design, and Baseline Data
Pagano, G, Boess, FG, Taylor, KI, Ricci, B, Mollenhauer, B, Poewe, W, Boulay, A, Anzures-Cabrera, J, Vogt, A, Marchesi, M, Post, A, Nikolcheva, T, Kinney, GG, Zago, WM, Ness, DK, Svoboda, H, Britschgi, M, Ostrowitzki, S, Simuni, T, Marek, K, Koller, M, Sevigny, J, Doody, R, Fontoura, P, Umbricht, D, Bonni, A, PASADENA Investigators, Bejr-Kasem, H, Bojarsky J.K., Prasinezumab Study Grp. A Phase II Study to Evaluate the Safety and Efficacy of Prasinezumab in Early Parkinson's Disease (PASADENA): Rationale, Design, and Baseline Data. Frontiers in Neurology. 2021; 12DOI:10.3389/fneur.2021.705407. PMID:34659081. IF:4.086(Q2/5D).
01/10/2021
The Recovery of Cognitive and Affective Deficiencies Linked with Chronic Osteoarthritis Pain and Implicated Pathways by Slow-Releasing Hydrogen Sulfide Treatment
Batalle, G, Bai, X, Pouso-Vazquez, E, Roch, G, Rodriguez, L, Pol, O. The Recovery of Cognitive and Affective Deficiencies Linked with Chronic Osteoarthritis Pain and Implicated Pathways by Slow-Releasing Hydrogen Sulfide Treatment. Antioxidants. 2021; 10(10)DOI:10.3390/antiox10101632. PMID:34679766. IF:7.675(Q1/1D).